Cochrane · systematic review · CD012619
Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis
Carroll, W, Green, J, Gilchrist, FJ · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
3
No studies
4
Included studies
NR
No studies 4 · 57.1%Ungraded 0 · 0%Very low 3 · 42.9%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsCisapride compared to placebo for preventing DIOS in cystic fibrosis
Population: people with cystic fibrosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Radiological diagnosis of DIOS (physician‐measured radiological scores) Cisapride vs placebo | no estimate extracted | 1 study · 17 participants | Very low Downgraded: risk of bias, imprecision |
Adverse effects (participant interviews) Cisapride vs placebo | no estimate extracted | 1 study · 17 participants | Very low Downgraded: risk of bias, imprecision |
Total gastrointestinal symptom scores (participant‐reported symptom scores from 20 to 100) Cisapride vs placebo | no estimate extracted | 1 study · 17 participants | Very low Downgraded: risk of bias, imprecision |
Hospitalisation for any cause Cisapride vs placebo | no estimate extracted | NR | No studies |
Hospitalisation for DIOS Cisapride vs placebo | no estimate extracted | NR | No studies |
Quality of life Cisapride vs placebo | no estimate extracted | NR | No studies |
Tolerability Cisapride vs placebo | no estimate extracted | NR | No studies |